| AGCT | Adult granulosa cell tumor |
| AML | Acute myeloid leukemia |
| ANZGOG | Australia New Zealand Gynaecological Oncology Group |
| ASCO | American Society of Clinical Oncology |
| BEP | Bleomycin–etoposide–cisplatin |
| EP | Etoposide–cisplatin |
| BEP/EP | Bleomycin–etoposide–cisplatin/etoposide–cisplatin |
| CP | Carboplatin–paclitaxel |
| CI | Confidence interval |
| CTCAE | Common Terminology Criteria for Adverse Events |
| DFS | Disease-free survival |
| DLCO | Diffusing capacity of the lung for carbon monoxide |
| ECOG | Eastern Cooperative Oncology Group |
| FIGO | International Federation of Gynecology and Obstetrics |
| HR | Hazard ratio |
| IC-NOS | Stage IC not otherwise specified |
| IQR | Interquartile range |
| NRG/GOG | NRG Oncology/Gynecologic Oncology Group |